

National Notifiable Infectious Diseases and Conditions: United States

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories - - United States, 2017
(Accessible Version: <https://wonder.cdc.gov/nndss/static/2017/annual/2017-table1.html>)

Disease	Case Count	Rate
Anthrax	—	—
Arboviral diseases		
Chikungunya virus disease	156	0.05
Eastern equine encephalitis virus disease		
Neuroinvasive	5	0.00
Non-neuroinvasive	—	—
Jamestown Canyon virus disease		
Neuroinvasive	58	0.02
Non-neuroinvasive	17	0.01
La Crosse virus disease		
Neuroinvasive	63	0.02
Non-neuroinvasive	—	—
Powassan virus disease		
Neuroinvasive	33	0.01
Non-neuroinvasive	1	0.00
St. Louis encephalitis virus disease		
Neuroinvasive	6	0.00
Non-neuroinvasive	5	0.00
West Nile virus disease		
Neuroinvasive	1,425	0.44
Non-neuroinvasive	672	0.21
Western equine encephalitis virus disease		
Neuroinvasive	—	—
Non-neuroinvasive	—	—
Babesiosis		
Total	2,368	0.94
Confirmed	1,994	0.79
Probable	374	0.15
Botulism		
Total	177	0.05
Foodborne	19	0.01
Infant *	137	3.48
Other (wound & unspecified)	21	0.01
Brucellosis	140	0.04
Campylobacteriosis	67,537	20.73
Chancroid	7	0.00
<i>Chlamydia trachomatis</i> infection	1,708,569	524.55
Cholera	10	0.00
Coccidioidomycosis †	14,364	10.93
Cryptosporidiosis		
Total	11,414	3.50
Confirmed	8,043	2.47
Probable	3,371	1.03
Cyclosporiasis	1,194	0.40
Dengue virus infections §		
Dengue	437	0.13
Dengue-like illness	8	0.00
Severe dengue	9	0.00
Diphtheria	—	—
Ehrlichiosis and Anaplasmosis		
<i>Anaplasma phagocytophilum</i> infection	5,762	1.83
<i>Ehrlichia chaffeensis</i> infection	1,642	0.52
<i>Ehrlichia ewingii</i> infection	45	0.01
Undetermined ehrlichiosis/anaplasmosis	269	0.09

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories -- United States, 2017
 (Accessible Version: <https://wonder.cdc.gov/nndss/static/2017/annual/2017-table1.html>)

Disease	Case Count	Rate
Giardiasis	15,193	5.94
Gonorrhea	555,608	170.58
<i>Haemophilus influenzae</i> , invasive disease		
All ages, all serotypes	5,548	1.70
Age <5 years ¶¶		
Serotype b	33	0.17
Non-b serotype	189	0.95
Nontypeable	200	1.00
Unknown serotype	203	1.02
Hansen's disease	94	0.03
Hantavirus infection, non-hantavirus pulmonary syndrome	2	0.00
Hantavirus pulmonary syndrome	33	0.01
Hemolytic uremic syndrome post-diarrheal	338	0.11
Hepatitis **		
A, acute	3,365	1.03
B, acute	3,409	1.05
B, perinatal infection ††	31	0.39
C, acute	4,225	1.36
Confirmed	3,213	1.04
Probable	1,012	0.33
Human immunodeficiency virus diagnoses	33,938	10.42
Influenza-associated pediatric mortality §§	126	0.17
Invasive pneumococcal disease ¶¶¶		
All ages	19,780	8.15
Confirmed	19,620	8.08
Probable	160	0.07
Age <5 years ¶¶	1,234	0.47
Confirmed	1,220	7.64
Probable	14	0.09
Legionellosis	7,458	2.29
Leptospirosis	72	0.03
Listeriosis	887	0.27
Lyme disease		
Total	42,743	13.18
Confirmed	29,513	9.10
Probable	13,230	4.08
Malaria	2,056	0.63
Measles		
Total	120	0.04
Indigenous	99	0.03
Imported	21	0.01
Meningococcal disease		
All serogroups	353	0.11
Serogroups ACWY	107	0.03
Serogroup B	90	0.03
Other serogroups	25	0.01
Unknown serogroup	131	0.04
Mumps	6,109	1.88
Novel Influenza A virus infections	66	0.02
Pertussis	18,975	5.83
Plague	5	0.00
Poliomyelitis, paralytic	—	—
Poliovirus infection, nonparalytic	—	—
Psittacosis	5	0.00
Q fever		
Total	193	0.06
Acute	153	0.05
Chronic	40	0.01

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories -- United States, 2017
(Accessible Version: <https://wonder.cdc.gov/nndss/static/2017/annual/2017-table1.html>)

Disease	Case Count	Rate
Rabies		
Animal	4,423	1.36
Human	2	0.00
Rubella	7	0.00
Rubella, congenital syndrome *	5	0.13
Salmonellosis	54,285	16.67
Severe acute respiratory syndrome-associated coronavirus disease	—	—
Shiga toxin-producing <i>Escherichia coli</i> ***	8,672	2.66
Shigellosis	14,912	4.58
Smallpox	—	—
Spotted fever rickettsiosis		
Total	6,248	1.93
Confirmed	176	0.05
Probable	6,072	1.88
Streptococcal toxic shock syndrome	372	0.18
Syphilis		
Total, all stages	101,567	31.18
Congenital *	918	23.30
Primary and secondary	30,644	9.41
Tetanus	33	0.01
Toxic shock syndrome (other than Streptococcal)	30	0.01
Trichinellosis	15	0.00
Tuberculosis	9,105	2.80
Tularemia	239	0.07
Typhoid fever	419	0.13
Vancomycin-intermediate <i>Staphylococcus aureus</i>	109	0.04
Vancomycin-resistant <i>Staphylococcus aureus</i>	3	0.00
Varicella morbidity	8,775	3.30
Varicella mortality	2	0.00
Vibriosis		
Total	2,085	0.65
Confirmed	1,497	0.47
Probable	588	0.18
Viral hemorrhagic fevers		
Crimean-Congo hemorrhagic fever virus	—	—
Ebola virus	—	—
Guanarito virus	—	—
Junin virus	—	—
Lassa virus	—	—
Lujo virus	—	—
Machupo virus	—	—
Marburg virus	—	—
Sabia virus	—	—
Yellow fever	—	—
Zika virus		
Zika virus disease, congenital *,†††	22	0.56
Zika virus disease, non-congenital	497	0.15
Zika virus infection, congenital *,†††	17	0.43
Zika virus infection, non-congenital	641	0.20

—: No reported cases — The reporting jurisdiction did not submit any cases to CDC.

* The rate is calculated using population less than 1 year of age.

† Reportable in <25 states.

§ Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).

¶ The rate is calculated using population less than 5 years of age.

** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at <https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm>.

†† The rate is calculated using population less than 2 years of age.

§§ The rate is calculated using population less than 18 years of age.

¶¶ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named *Streptococcus pneumoniae* invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.

*** Includes *Escherichia coli* O157:H7 and Shiga toxin-positive *Escherichia coli* (including O157, non-O157, and not serogrouped).

††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at <https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html>. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.

Notes:

- These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
- The list of national notifiable infectious diseases and conditions for 2017 and their national surveillance case definitions are available at <https://www.cdc.gov/nndss/conditions/notifiable/2017/infectious-diseases/>. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2016 by CSTE for national surveillance, that were implemented in January 2017, including updated surveillance case definitions for salmonellosis, shigellosis, vibriosis, perinatal hepatitis B virus infection, invasive pneumococcal disease, Lyme disease, and tularemia reported through August 7, 2018. Publication criteria for the finalized 2017 data are available at https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf. See also [Guide to Interpreting Provisional and Finalized NNDSS Data](#).
- Population estimates for incidence rates are July 1st, 2017 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2017, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2017), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 27, 2018 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2017 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on October 2, 2018 at <https://www.census.gov/data-tools/demo/idb/informationGateway.php>. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
- Annual tables for 2016 and later years are available on [CDC WONDER](#).
- Annual summary reports from 1993-2015 are available as published in the *MMWR*.
- NNDSS annual tables since 1952 are available at [CDC Stacks](#) (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).

Suggested Citation:

- Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2017 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2018. Available at: <https://www.cdc.gov/nndss/infectious-tables.html>.

National Notifiable Diseases Surveillance System

Provided by [CDC WONDER](#)